Welcome!

Web 2.0 Authors: Roger Strukhoff, Carmen Gonzalez, Trevor Parsons, Lori MacVittie, Travis Olague

News Feed Item

Amgen's Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51

Full Year 2012 GAAP EPS Were $5.52

THOUSAND OAKS, Calif., Jan. 23, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2012. Key results include:

  • For the full year, total revenues increased 11 percent to $17,265 million, with 9 percent product sales growth driven by strong performance across the portfolio. Adjusted EPS grew 22 percent to $6.51 due to 15 percent adjusted operating income growth and lower shares outstanding. 
  • For the fourth quarter, total revenues increased 11 percent to $4,421 million, with product sales growing at the same rate. Adjusted EPS grew 16 percent to $1.40 due to 11 percent adjusted operating income growth and lower shares outstanding. 
  • GAAP EPS were $1.01 in the fourth quarter compared to $1.08 a year ago, and were $5.52 for the full year compared to $4.04 in 2011. Full year 2011 was negatively impacted by a previously disclosed charge for a legal settlement reserve.
  • Free cash flow for the full year was $5.2 billion compared to $4.5 billion in 2011.
  • The Company announced that it has initiated Phase 3 studies for AMG 145 in subjects with high levels of low-density lipoprotein (LDL) cholesterol. 

"We achieved strong operating performance in 2012 as we delivered for patients and created value for shareholders," said Robert A. Bradway, chairman and chief executive officer at Amgen.  "We enter 2013 with good momentum, a broad late-stage pipeline and a continued focus on building our business internationally."



Year-over-Year


Year-over-Year

$Millions, except EPS and percentages


Q4 '12


Q4 '11


YOY Δ


FY '12


FY '11


YOY Δ














Total Revenues


$4,421


$3,973


11%


$17,265


$15,582


11%

Adjusted Net Income


1,088


1,039


5%


5,119


4,858


5%

Adjusted EPS


1.40


1.21


16%


6.51


5.33


22%














GAAP Net Income


788


934


(16%)


4,345


3,683


18%

GAAP EPS


$1.01


$1.08


(6%)


$5.52


$4.04


37%

References in this release to "adjusted" measures, measures presented "on an adjusted basis" or to free cash flow refer to non-GAAP financial measures.  These adjustments and other items are presented on the attached reconciliations.

 

Product Sales Performance

  • Total product sales increased 9 percent for the full year, driven by strong performance across the portfolio.  Product sales increased 11 percent for the fourth quarter of 2012 versus the fourth quarter of 2011 driven by Enbrel® (etanercept), XGEVA® (denosumab) and Prolia® (denosumab).
  • Combined Neulasta® (pegfilgrastim) and NEUPOGEN® (Filgrastim) sales declined 1 percent for the fourth quarter of 2012 versus the fourth quarter of 2011, and increased 3 percent for the full year.
    • Global Neulasta sales for the fourth quarter of 2012 versus the fourth quarter of 2011 were flat as price increases were offset by unit declines and unfavorable inventory changes. Sales increased 4 percent for the full year mainly due to price increases.
    • Global NEUPOGEN sales for the fourth quarter of 2012 versus the fourth quarter of 2011 declined 3 percent driven by a decrease in unit demand from loss of share to biosimilars in Europe. Sales were flat for the full year as price increases offset unit declines.
  • ENBREL sales for the fourth quarter of 2012 versus the fourth quarter of 2011 increased 23 percent driven by increases in the average net sales price and unit demand. Sales increased 14 percent for the full year due mainly to price increases and unit growth.
  • Aranesp® (darbepoetin alfa) sales decreased 9 percent for the fourth quarter of 2012 versus the fourth quarter of 2011 and 11 percent for the full year due to changes in practice patterns.  Sequentially, sales were down 2 percent. 
  • EPOGEN® (epoetin alfa) sales for the fourth quarter of 2012 versus the fourth quarter of 2011 decreased 1 percent driven by a reduction in dose utilization, offset largely by a reduction in customer discounts and favorable changes in accounting estimates. Sales for the full year decreased 5 percent as unit declines were offset partially by a reduction in customer discounts and favorable changes in accounting estimates.
  • Sensipar®/Mimpara® (cinacalcet) sales increased 19 percent for the fourth quarter of 2012 versus the fourth quarter of 2011 and 18 percent for the full year due to unit growth and price increases.
  • Combined sales of Vectibix® (panitumumab) and Nplate® (romiplostim) increased 15 percent for the fourth quarter of 2012 versus the fourth quarter of 2011 and 17 percent for the full year due to unit growth.
  • XGEVA sales increased 7 percent on a sequential basis and 113 percent for the full year due to unit growth.
  • Prolia sales increased 40 percent on a sequential basis and 133 percent for the full year due to unit growth.  

Product Sales Detail by Product and Geographic Region

$Millions, except percentages


Q4 '12


Q4 '11


YOY Δ



US

ROW

TOTAL


TOTAL


TOTAL










Neulasta®/ NEUPOGEN®


$1,026

$280

$1,306


$1,319


(1%)

Neulasta®


775

219

994


998


0%

NEUPOGEN®


251

61

312


321


(3%)

Enbrel®


1,086

75

1,161


945


23%

Aranesp®


187

302

489


538


(9%)

EPOGEN®


479

0

479


486


(1%)

Sensipar® / Mimpara®


177

79

256


216


19%

Vectibix®


30

61

91


87


5%

Nplate®


57

44

101


80


26%

XGEVA®


178

37

215


134


60%

Prolia®


95

59

154


81


90%

Other 


0

85

85


21


*










Total product sales


$3,315

$1,022

$4,337


$3,907


11%










* Change in excess of 100%









 

$Millions, except percentages


FY '12


FY '11


YOY Δ



US

ROW

TOTAL


TOTAL


TOTAL










Neulasta®/ NEUPOGEN®


$4,214

$1,138

$5,352


$5,212


3%

Neulasta®


3,207

885

4,092


3,952


4%

NEUPOGEN®


1,007

253

1,260


1,260


0%

Enbrel®


3,967

269

4,236


3,701


14%

Aranesp®


782

1,258

2,040


2,303


(11%)

EPOGEN®


1,941

0

1,941


2,040


(5%)

Sensipar® / Mimpara®


639

311

950


808


18%

Vectibix®


122

237

359


322


11%

Nplate®


214

154

368


297


24%

XGEVA®


644

104

748


351


*

Prolia®


292

180

472


203


*

Other 


0

173

173


58


*










Total product sales


$12,815

$3,824

$16,639


$15,295


9%










* Change in excess of 100%









Operating Expense and Tax Rate Analysis, on an Adjusted Basis

  • Cost of Sales, excluding the impact of the Puerto Rico excise tax, increased 0.3 points to 14.7 percent in the fourth quarter of 2012 and increased 0.4 points to 14.4 percent for the full year due to product mix, offset partially by manufacturing efficiencies and higher average net sales price. 
  • Research & Development (R&D) expenses increased 9 percent in the fourth quarter of 2012 driven by later-stage clinical programs, primarily AMG 145 and romosozumab (AMG 785). For the full year, R&D expenses increased 6 percent driven by later-stage clinical programs, primarily AMG 145 and romosozumab (AMG 785), offset partially by reduced expenses associated with marketed product support.
  • Selling, General & Administrative (SG&A) expenses increased 13 percent in the fourth quarter of 2012 driven by higher ENBREL profit share expenses and international expansion.  ENBREL profit share expenses increased 27 percent to $414 million in the fourth quarter.  For the full year, SG&A expenses increased 6 percent, driven primarily by higher ENBREL profit share expenses and international expansion, offset partially by a favorable change to the estimated U.S. healthcare reform federal excise fee. ENBREL profit share expenses increased 16 percent to $1,495 million in 2012.

$Millions, except percentages












On an Adjusted Basis


Q4 '12


Q4 '11


YOY Δ


FY '12


FY '11


YOY Δ
















Cost of Sales

$727


$643


13%


$2,735


$2,345


17%


% of sales

16.8%


16.5%


0.3 pts


16.4%


15.3%


1.1 pts


% of sales (Excluding PR excise tax)

14.7%


14.4%


0.3 pts


14.4%


14.0%


0.4 pts

Research & Development

$917


$842


9%


$3,296


$3,116


6%


% of sales

21.1%


21.6%


(0.5) pts


19.8%


20.4%


(0.6) pts

Selling, General & Administrative

$1,351


$1,199


13%


$4,717


$4,434


6%


% of sales

31.2%


30.7%


0.5 pts


28.3%


29.0%


(0.7) pts

TOTAL Operating Expenses

$2,995


$2,684


12%


$10,748


$9,895


9%

pts: percentage points











 

  • Tax Rate increased by 1.8 points to 16.1 percent in the fourth quarter of 2012 due primarily to the unfavorable tax impact of changes in the jurisdictional mix of income and expenses, as well as the benefit in the fourth quarter of 2011 from the federal R&D tax credit which was not reinstated prior to 2012 year-end. This increase was offset partially by the favorable resolution of certain state tax matters related to prior years. For the full year, the adjusted tax rate increased 1.6 points to 15.9 percent due primarily to the federal R&D tax credit included in 2011 but not in 2012, the unfavorable tax impact of changes in the jurisdictional mix of income and expenses, offset partially by the favorable resolution of certain state tax matters related to prior years. 













On an Adjusted Basis


Q4 '12


Q4 '11


YOY Δ


FY '12


FY '11


YOY Δ
















Tax Rate

16.1%


14.3%


1.8 pts


15.9%


14.3%


1.6 pts

Tax Rate (Excluding PR excise tax credits)

20.3%


18.1%


2.2 pts


20.3%


19.2%


1.1 pts

pts: percentage points













Cash Flow and Balance Sheet Discussion

  • The Company generated $0.6 billion of free cash flow in the fourth quarter of 2012 versus $1.4 billion in the fourth quarter of 2011. The decrease was driven by a $0.8 billion payment related to a previously disclosed legal settlement. For the full year, free cash flow increased $0.7 billion to $5.2 billion driven by improved collections of receivables, termination of fixed to floating interest rate swap agreements, and higher net income, offset partially by the aforementioned legal settlement payment.
  • During the fourth quarter, Amgen repurchased approximately 14 million shares of common stock at a total cost of $1.2 billion and at an average price of $86.56. This brings the total shares repurchased under its $10 billion authorized stock repurchase program to 146 million at a total cost of $9.7 billion and at an average price of $66.37. The Company previously announced a $2 billion increase in share repurchase authorization by its Board of Directors. Amgen expects that this increase will cover the Company's share repurchase activity into 2014.
  • The Company previously announced that its Board of Directors declared a $0.47 per share dividend for the first quarter of 2013. The dividend will be paid on March 7, 2013, to all stockholders of record as of the close of business on Feb. 13, 2013. This represents a 31 percent increase from that paid in each of the previous four quarters.

$Billions, except shares


Q4 '12


Q4 '11


YOY Δ


FY '12


FY '11


YOY Δ
















Operating Cash Flow

$0.8


$1.6


($0.8)


$5.9


$5.1


$0.8

Capital Expenditures

0.2


0.2


0.0


0.7


0.6


0.1

Free Cash Flow

0.6


1.4


(0.8)


5.2


4.5


0.7

Dividend Paid

0.3


0.2


0.1


1.1


0.5


0.6

Cost of Shares Repurchased

1.2


5.2


(4.0)


4.7


8.3


(3.6)

Adjusted Avg. Diluted Shares (millions)

778


860


(82)


786


912


(126)
















Cash Balance

24.1


20.6


3.5


24.1


20.6


3.5

Adjusted Debt Outstanding

26.5


21.6


4.9


26.5


21.6


4.9

Stockholders' Equity

19.1


19.0


0.1


19.1


19.0


0.1

Note: Numbers may not add due to rounding











2013 Guidance

For the full year 2013, the Company expects:

  • Total revenues to be in the range of $17.8 billion to $18.2 billion and adjusted EPS to be in the range of $6.85 to $7.15.
  • Adjusted tax rate to be in the range of 14 percent to 15 percent. This reflects the impact of the foreign tax credit associated with the Puerto Rico excise tax. Excluding the Puerto Rico excise tax, Amgen expects the adjusted tax rate for 2013 to be in the range of 17 percent to 18 percent.
  • Capital expenditures to be approximately $700 million.

Product and Pipeline Update

  • AMG 145:  The Company recently initiated Phase 3 studies in subjects with high levels of LDL cholesterol.
  • Trebananib (AMG 386):  Enrollment has resumed for the Phase 3 study in recurrent ovarian cancer that was previously suspended due to DOXIL® (doxorubicin HCl liposome injection) supply issues.
  • Aranesp:  The Company announced top-line results of the Phase 3 RED-HF® (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.
  • deCODE Genetics:  The Company completed the acquisition of deCODE Genetics in December 2012.

Non-GAAP Financial Measures
The Adjusted non-GAAP (U.S. Generally Accepted Accounting Principles) financial measures included above for the three and twelve months ended Dec. 31, 2012 and 2011 exclude, for the applicable periods, certain expenses related to acquisitions, cost-savings initiatives, various legal proceedings, non-cash interest expense associated with our convertible notes and certain other adjustments, as applicable. These adjustments and other items are presented on the attached reconciliations.

Management has presented its operating results in accordance with GAAP and on an "adjusted" (or non-GAAP) basis and Free Cash Flow which is a non-GAAP financial measure for the three and twelve months ended Dec. 31, 2012 and 2011. In addition, management has presented its outstanding debt in accordance with GAAP and on an "adjusted" (or non-GAAP) basis as of Dec. 31, 2012 and 2011. The Company believes that the presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses these non-GAAP financial measures in connection with its own budgeting and financial planning.  These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in conformity with GAAP.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2011, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. 

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

 

Amgen Inc.

Condensed Consolidated Statements of Income - GAAP

(In millions, except per share data)

(Unaudited)
















Three months ended


Years ended





December 31, 


December 31, 





2012


2011


2012


2011

Revenues:










Product sales


$  4,337


$       3,907


$ 16,639


$ 15,295


Other revenues


84


66


626


287



Total revenues


4,421


3,973


17,265


15,582












Operating expenses:










Cost of sales (excludes amortization of certain











acquired intangible assets presented below)


852


656


2,918


2,427


Research and development


938


851


3,380


3,167


Selling, general and administrative


1,370


1,208


4,801


4,486


Amortization of certain acquired intangible assets


73


73


294


294


Other


100


23


295


896



Total operating expenses


3,333


2,811


11,688


11,270












Operating income


1,088


1,162


5,577


4,312












Interest expense, net


291


195


1,053


610

Interest and other income, net


126


84


485


448












Income before income taxes


923


1,051


5,009


4,150












Provision for income taxes


135


117


664


467












Net income


$     788


$          934


$   4,345


$   3,683












Earnings per share:










Basic


$    1.03


$         1.09


$     5.61


$     4.07


Diluted


$    1.01


$         1.08


$     5.52


$     4.04












Average shares used in calculation










of earnings per share:










Basic


763


854


775


905


Diluted


778


861


787


912























 

Amgen Inc.

Condensed Consolidated Balance Sheets - GAAP 

(In millions)

(Unaudited)











December 31, 


December 31, 





2012


2011


Assets






Current assets:






Cash, cash equivalents and marketable securities


$                 24,061


$                 20,641



Trade receivables, net


2,518


2,896



Inventories


2,744


2,484



Other current assets


1,886


1,572





Total current assets


31,209


27,593


Property, plant and equipment, net


5,326


5,420


Intangible assets, net


3,968


2,584


Goodwill


12,662


11,750


Other assets


1,133


1,524


Total assets


$                 54,298


$                 48,871









Liabilities and Stockholders' Equity






Current liabilities:







Accounts payable and accrued liabilities


$                   5,608


$                   5,670



Current portion of long-term debt


2,495


84





Total current liabilities


8,103


5,754


Long-term debt


24,034


21,344


Other non-current liabilities


3,101


2,744


Stockholders' equity


19,060


19,029


Total liabilities and stockholders' equity


$                 54,298


$                 48,871







Shares outstanding


756


796











Amgen Inc.


GAAP to "Adjusted" Reconciliations


(In millions)


(Unaudited)
























Three months ended


Years ended




December 31, 


December 31, 




2012


2011


2012


2011













GAAP cost of sales

$    852


$          656


$   2,918


$        2,427



Adjustments to cost of sales:










Certain charges pursuant to our continuing efforts to improve cost efficiencies in our operations (a)

(118)


(11)


(160)


(65)



Acquisition-related expenses

(4)


-


(11)


(7)



Stock option expense (b)

(3)


(2)


(12)


(10)



Total adjustments to cost of sales

(125)


(13)


(183)


(82)



Adjusted cost of sales

$    727


$          643


$   2,735


$        2,345























GAAP research and development expenses

$    938


$          851


$   3,380


$        3,167



Adjustments to research and development expenses:










Acquisition-related expenses

(16)


(1)


(50)


(28)



Certain charges pursuant to our continuing efforts to improve cost efficiencies in our operations

-


-


(12)


-



Reversal of previously accrued expenses for bonuses and stock-based compensation awards, which were forfeited as a result of the employees' termination pursuant to our continuing efforts to improve cost efficiencies in our operations

-


-


-


12



Stock option expense  (b)

(5)


(8)


(22)


(35)



Total adjustments to research and development expenses

(21)


(9)


(84)


(51)



Adjusted research and development expenses

$    917


$          842


$   3,296


$        3,116























GAAP selling, general and administrative expenses

$  1,370


$        1,208


$   4,801


$        4,486



Adjustments to selling, general and administrative expenses:










Acquisition-related expenses

(14)


(1)


(59)


(12)



Stock option expense (b)

(5)


(8)


(25)


(40)



Total adjustments to selling, general and administrative expenses

(19)


(9)


(84)


(52)



Adjusted selling, general and administrative expenses

$  1,351


$        1,199


$   4,717


$        4,434























GAAP operating expenses

$  3,333


$        2,811


$  11,688


$      11,270



Adjustments to operating expenses:










Adjustments to cost of sales

(125)


(13)


(183)


(82)



Adjustments to research and development expenses

(21)


(9)


(84)


(51)



Adjustments to selling, general and administrative expenses

(19)


(9)


(84)


(52)



Non-cash amortization of product technology rights acquired in a prior year business combination

(73)


(73)


(294)


(294)



Certain charges pursuant to our continuing efforts to improve cost efficiencies in our operations

(69)


(30)


(175)


(109)



Acquisition-related expenses

(6)


-


(25)


-



(Expense)/benefit resulting from changes in the estimated fair values of the contingent consideration obligations related to a prior year business combination

(26)


8


(31)


(1)



Benefit/(expenses) related to various legal proceedings

1


(1)


(64)


(786)



Total adjustments to operating expenses

(338)


(127)


(940)


(1,375)



Adjusted operating expenses

$  2,995


$        2,684


$  10,748


$        9,895























GAAP operating income

$  1,088


$        1,162


$   5,577


$        4,312



Adjustments to operating expenses

338


127


940


1,375



Adjusted operating income

$  1,426


$        1,289


$   6,517


$        5,687























GAAP income before income taxes

$    923


$        1,051


$   5,009


$        4,150



Adjustments to income before income taxes:










Adjustments to operating expenses

338


127


940


1,375



Non-cash interest expense associated with our convertible notes

36


34


140


143



Total adjustments to income before income taxes

374


161


1,080


1,518



Adjusted income before income taxes

$  1,297


$        1,212


$   6,089


$        5,668























GAAP provision for income taxes

$    135


$          117


$      664


$          467



Adjustments to provision for income taxes:










Income tax effect of the above adjustments (c)

97


56


329


331



Income tax net expense/(benefit) related to certain prior period items excluded from "Adjusted" earnings

(23)


-


(23)


12



Total adjustments to provision for income taxes

74


56


306


343



Adjusted provision for income taxes

$    209


$          173


$      970


$          810























GAAP net income

$    788


$          934


$   4,345


$        3,683



Adjustments to income before income taxes, net of the tax effect of the above adjustments

277


105


751


1,187



Income tax net expense/(benefit) related to certain prior period items excluded from "Adjusted" earnings

23


-


23


(12)



Adjusted net income

$  1,088


$        1,039


$   5,119


$        4,858






















Amgen Inc.

GAAP to "Adjusted" Reconciliations

(In millions, except per share data)

(Unaudited)



The following table presents the computations for GAAP and "Adjusted" diluted EPS, computed under the treasury stock method.


"Adjusted" EPS presented below excludes stock option expense:













Three months ended


Three months ended




December 31, 2012


December 31, 2011




GAAP


"Adjusted"  


GAAP


"Adjusted"  



Income (Numerator):










Net income for basic and diluted EPS

$    788


$        1,088


$      934


$        1,039













Shares (Denominator):










Weighted-average shares for basic EPS

763


763


854


854



Effect of dilutive securities

15


15

(*)

7


6

(*)


Weighted-average shares for diluted EPS

778


778


861


860













Diluted EPS

$   1.01


$         1.40


$     1.08


$         1.21














Year ended


Year ended




December 31, 2012


December 31, 2011




GAAP


"Adjusted" 


GAAP


"Adjusted" 



Income (Numerator):










Net income for basic and diluted EPS

$  4,345


$        5,119


$   3,683


$        4,858













Shares (Denominator):










Weighted-average shares for basic EPS

775


775


905


905



Effect of dilutive securities

12


11

(*)

7


7

(*)


Weighted-average shares for diluted EPS

787


786


912


912













Diluted earnings per share

$   5.52


$         6.51


$     4.04


$         5.33













(*)  Dilutive securities used to compute "Adjusted" diluted EPS for the three months and years ended December 31, 2012 and 2011 were computed under the treasury stock method assuming that we do not expense stock options.











(a)

The adjustments during the years ended 2012 and 2011 include incremental expenses resulting from our transaction with Boehringer Ingelheim.  The adjustment during the three months ended December 31, 2012, relates to a charge in connection with the rationalization of our worldwide manufacturing operations.











(b)

For the three months and years ended December 31, 2012 and 2011, the total pre-tax expense for employee stock options was $13 million and $59 million, respectively and $18 million and $85 million, respectively.






















"Adjusted" diluted EPS including the impact of stock option expense for the three months and years ended December 31, 2012 and 2011 was as follows: 













Three months ended


Years ended




December 31, 


December 31, 




2012


2011


2012


2011













"Adjusted" diluted EPS, excluding stock option expense

$   1.40


$         1.21


$     6.51


$         5.33













Impact of stock option expense (net of tax)

(0.01)


(0.02)


(0.06)


(0.07)













"Adjusted" diluted EPS, including stock option expense

$   1.39


$         1.19


$     6.45


$         5.26












(c)

The tax effect of the adjustments between our GAAP and "Adjusted" results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s).  Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including amortization of intangible assets and non-cash interest expense associated with our convertible notes, whereas the tax impact of other adjustments, including stock option expense, depends on whether the amounts are deductible in the tax jurisdictions where the expenses are incurred or the asset is located and the applicable tax rate(s) in those jurisdictions. Due to these factors, the effective tax rates for the adjustments to our GAAP income before income taxes, for the three months and years ended December 31, 2012, were 25.9% and 30.5%, respectively, compared with 34.8% and 21.8% for the corresponding periods of the prior year.






Amgen Inc.

Reconciliation of GAAP Debt Outstanding to "Adjusted" Debt Outstanding

(In millions)

(Unaudited)





GAAP


Adjustments for accounting standard (a)


"Adjusted"

















December 31, 2011

$           21,428


$                  154


$           21,582






December 31, 2012

$           26,529


$                    12


$           26,541







(a)

To exclude the impact of bifurcating the debt and equity components of our convertible notes as required by U.S. accounting standards for these securities commencing in 2009.


 

Reconciliation of Free Cash Flow

(In millions)

(Unaudited)












Three months ended


Years ended



December 31, 


December 31,



2012


2011


2012


2011


Cash Flows from Operations

$                       812


$                  1,584


$              5,882


$              5,119


Capital Expenditures

(200)


(224)


(689)


(567)


Free Cash Flow

$                       612


$                  1,360


$              5,193


$              4,552










Amgen Inc.

Reconciliation of GAAP EPS Guidance to "Adjusted" 

EPS Guidance for the Year Ending December 31, 2013

(Unaudited)



























2013


















GAAP EPS (diluted) guidance


$        6.46

-

$        6.76


















Known adjustments to arrive at "Adjusted" earnings*:












Amortization of acquired intangible assets

(a)

0.34








Stock option expense

(b)

0.04








Non-cash interest expense associated with our convertible notes

(c)

0.01


















"Adjusted" EPS (diluted) guidance


$        6.85

-

$        7.15









*

The known adjustments are presented net of their related aggregate tax impact of approximately $0.19 per share. 



(a)

To exclude the non-cash amortization of intangible assets acquired in prior year business combinations.



(b)

To exclude stock option expense.



(c)

To exclude the non-cash interest expense associated with our convertible notes.




Reconciliation of GAAP Tax Rate Guidance to "Adjusted" 

Tax Rate Guidance for the Year Ending December 31, 2013

(Unaudited)




2013 with PR excise tax credit


2013 without PR excise tax credit












GAAP tax rate guidance

12.5%

-

13.6%



15.8%

-

16.9%














Tax rate effect of known adjustments discussed above

1.5%

-

1.4%



1.2%

-

1.1%













"Adjusted" tax rate guidance

14.0%

-

15.0%



17.0%

-

18.0%













 

 

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

SOURCE Amgen

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
All major researchers estimate there will be tens of billions devices – computers, smartphones, tablets, and sensors – connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be!
Noted IoT expert and researcher Joseph di Paolantonio (pictured below) has joined the @ThingsExpo faculty. Joseph, who describes himself as an “Independent Thinker” from DataArchon, will speak on the topic of “Smart Grids & Managing Big Utilities.” Over his career, Joseph di Paolantonio has worked in the energy, renewables, aerospace, telecommunications, and information technology industries. His expertise is in data analysis, system engineering, Bayesian statistics, data warehouses, business intelligence, data mining, predictive methods, and very large databases (VLDB). Prior to DataArchon, he served as a VP and Principal Analyst with Constellation Group. He is a member of the Boulder (Colo.) Brain Trust, an organization with a mission “to benefit the Business Intelligence and data management industry by providing pro bono exchange of information between vendors and independent analysts on new trends and technologies and to provide vendors with constructive feedback on their of...
Software AG helps organizations transform into Digital Enterprises, so they can differentiate from competitors and better engage customers, partners and employees. Using the Software AG Suite, companies can close the gap between business and IT to create digital systems of differentiation that drive front-line agility. We offer four on-ramps to the Digital Enterprise: alignment through collaborative process analysis; transformation through portfolio management; agility through process automation and integration; and visibility through intelligent business operations and big data.
There will be 50 billion Internet connected devices by 2020. Today, every manufacturer has a propriety protocol and an app. How do we securely integrate these "things" into our lives and businesses in a way that we can easily control and manage? Even better, how do we integrate these "things" so that they control and manage each other so our lives become more convenient or our businesses become more profitable and/or safe? We have heard that the best interface is no interface. In his session at Internet of @ThingsExpo, Chris Matthieu, Co-Founder & CTO at Octoblu, Inc., will discuss how these devices generate enough data to learn our behaviors and simplify/improve our lives. What if we could connect everything to everything? I'm not only talking about connecting things to things but also systems, cloud services, and people. Add in a little machine learning and artificial intelligence and now we have something interesting...
Last week, while in San Francisco, I used the Uber app and service four times. All four experiences were great, although one of the drivers stopped for 30 seconds and then left as I was walking up to the car. He must have realized I was a blogger. None the less, the next car was just a minute away and I suffered no pain. In this article, my colleague, Ved Sen, Global Head, Advisory Services Social, Mobile and Sensors at Cognizant shares his experiences and insights.
We are reaching the end of the beginning with WebRTC and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will want to use their existing identities, but these will have credentials already that are (hopefully) irreversibly encoded. In his session at Internet of @ThingsExpo, Peter Dunkley, Technical Director at Acision, will look at how this identity problem can be solved and discuss ways to use existing web identities for real-time communication.
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of WebRTC adoption today, but the potential is limitless when powered by IoT. Attendees will learn real-world benefits of WebRTC and explore future possibilities, as WebRTC and IoT intersect to improve customer service.
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at Internet of @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, will share some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, deploy, and manage applications integrating voice, video and data. He is the co-founder of TeleStax, an Open Source Cloud Communications company that helps the shift from legacy IN/SS7 telco networks to IP-based cloud comms. An early investor in multiple start-ups, he still finds time to code for his companies and contribute to open source projects.
The Internet of Things (IoT) promises to create new business models as significant as those that were inspired by the Internet and the smartphone 20 and 10 years ago. What business, social and practical implications will this phenomenon bring? That's the subject of "Monetizing the Internet of Things: Perspectives from the Front Lines," an e-book released today and available free of charge from Aria Systems, the leading innovator in recurring revenue management.
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges.
There’s Big Data, then there’s really Big Data from the Internet of Things. IoT is evolving to include many data possibilities like new types of event, log and network data. The volumes are enormous, generating tens of billions of logs per day, which raise data challenges. Early IoT deployments are relying heavily on both the cloud and managed service providers to navigate these challenges. In her session at 6th Big Data Expo®, Hannah Smalltree, Director at Treasure Data, to discuss how IoT, Big Data and deployments are processing massive data volumes from wearables, utilities and other machines.
P2P RTC will impact the landscape of communications, shifting from traditional telephony style communications models to OTT (Over-The-Top) cloud assisted & PaaS (Platform as a Service) communication services. The P2P shift will impact many areas of our lives, from mobile communication, human interactive web services, RTC and telephony infrastructure, user federation, security and privacy implications, business costs, and scalability. In his session at Internet of @ThingsExpo, Erik Lagerway, Co-founder of Hookflash, will walk through the shifting landscape of traditional telephone and voice services to the modern P2P RTC era of OTT cloud assisted services.
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a video monitor. This leads to confusion and lack of understanding among participants especially regarding who is actually speaking. Spatial teleconferencing introduces the concept of acoustic spatial separation between conference participants in three dimensional space. This has been shown to significantly improve comprehension and conference efficiency.
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, will discuss single-value, geo-spatial, and log time series data. By focusing on enterprise applications and the data center, he will use OpenTSDB as an example to explain some of these concepts including when to use different storage models.
SYS-CON Events announced today that Gridstore™, the leader in software-defined storage (SDS) purpose-built for Windows Servers and Hyper-V, will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Gridstore™ is the leader in software-defined storage purpose built for virtualization that is designed to accelerate applications in virtualized environments. Using its patented Server-Side Virtual Controller™ Technology (SVCT) to eliminate the I/O blender effect and accelerate applications Gridstore delivers vmOptimized™ Storage that self-optimizes to each application or VM across both virtual and physical environments. Leveraging a grid architecture, Gridstore delivers the first end-to-end storage QoS to ensure the most important App or VM performance is never compromised. The storage grid, that uses Gridstore’s performance optimized nodes or capacity optimized nodes, starts with as few a...
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace. These technological reforms have not only changed computers and smartphones, but are also changing the data processing model for all information devices. In particular, in the area known as M2M (Machine-To-Machine), there are great expectations that information with a new type of value can be produced using a variety of devices and sensors saving/sharing data via the network and through large-scale cloud-type data processing. This consortium believes that attaching a huge number of devic...
Innodisk is a service-driven provider of industrial embedded flash and DRAM storage products and technologies, with a focus on the enterprise, industrial, aerospace, and defense industries. Innodisk is dedicated to serving their customers and business partners. Quality is vitally important when it comes to industrial embedded flash and DRAM storage products. That’s why Innodisk manufactures all of their products in their own purpose-built memory production facility. In fact, they designed and built their production center to maximize manufacturing efficiency and guarantee the highest quality of our products.
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. Download Slide Deck: ▸ Here
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. Over the summer Gartner released its much anticipated annual Hype Cycle report and the big news is that Internet of Things has now replaced Big Data as the most hyped technology. Indeed, we're hearing more and more about this fascinating new technological paradigm. Every other IT news item seems to be about IoT and its implications on the future of digital business.
BSQUARE is a global leader of embedded software solutions. We enable smart connected systems at the device level and beyond that millions use every day and provide actionable data solutions for the growing Internet of Things (IoT) market. We empower our world-class customers with our products, services and solutions to achieve innovation and success. For more information, visit www.bsquare.com.